135 related articles for article (PubMed ID: 21110823)
1. Bcl-2 targeted-therapy for the treatment of head and neck squamous cell carcinoma.
dos Santos LV; Carvalho AL
Recent Pat Anticancer Drug Discov; 2011 Jan; 6(1):45-57. PubMed ID: 21110823
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin and head and neck squamous cell carcinoma.
Liao YM; Kim C; Yen Y
Head Neck Oncol; 2011 Apr; 3():22. PubMed ID: 21513566
[TBL] [Abstract][Full Text] [Related]
4. Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications.
Schmitz S; Machiels JP
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1471-84. PubMed ID: 20836682
[TBL] [Abstract][Full Text] [Related]
5. RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma.
Arai A; Chano T; Futami K; Furuichi Y; Ikebuchi K; Inui T; Tameno H; Ochi Y; Shimada T; Hisa Y; Okabe H
Cancer Res; 2011 Jul; 71(13):4598-607. PubMed ID: 21571861
[TBL] [Abstract][Full Text] [Related]
6. Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.
Zerp SF; Stoter TR; Hoebers FJ; van den Brekel MW; Dubbelman R; Kuipers GK; Lafleur MV; Slotman BJ; Verheij M
Radiat Oncol; 2015 Jul; 10():158. PubMed ID: 26223311
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
8. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
10. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
11. A cDNA microarray analysis identifies 52 genes associated with cis-diamminedichloroplatinum susceptibility in head and neck squamous cell carcinoma cell lines.
Ogawa T; Furukawa T; Shiga K; Hashimoto S; Ogawa K; Kobayashi T; Horii A
Eur Arch Otorhinolaryngol; 2010 Jan; 267(1):123-9. PubMed ID: 19381670
[TBL] [Abstract][Full Text] [Related]
12. [Bcl-XL and bcl-2 expression in squamous epithelial carcinomas of the head-neck].
Budach W
Strahlenther Onkol; 1999 Oct; 175(10):533-4. PubMed ID: 10554650
[No Abstract] [Full Text] [Related]
13. The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer.
O'Bryan KW; Ratner D
Semin Cutan Med Surg; 2011 Mar; 30(1):57-61. PubMed ID: 21540021
[TBL] [Abstract][Full Text] [Related]
14. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
Chan LP; Chou TH; Ding HY; Chen PR; Chiang FY; Kuo PL; Liang CH
Biochim Biophys Acta; 2012 Jul; 1820(7):1081-91. PubMed ID: 22554915
[TBL] [Abstract][Full Text] [Related]
15. Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer.
Fury MG; Pfister DG
J Natl Compr Canc Netw; 2011 Jun; 9(6):681-9. PubMed ID: 21636539
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
17. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 as a target in laryngeal squamous cell carcinoma.
S Mastronikolis N; Tsiambas E; Fotiades PP; Ragos V
J BUON; 2019; 24(2):865. PubMed ID: 31128052
[No Abstract] [Full Text] [Related]
19. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
Juergens RA; Bratman SV; Tsao MS; Laurie SA; Sara Kuruvilla M; Razak AR; Hansen AR
Cancer Treat Rev; 2017 Mar; 54():43-57. PubMed ID: 28192747
[TBL] [Abstract][Full Text] [Related]
20. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
